Malin Lindstedt
Overview
Explore the profile of Malin Lindstedt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reste M, Ajazi K, Sayi-Yazgan A, Jankovic R, Bufan B, Brandau S, et al.
Front Immunol
. 2025 Feb;
16:1538818.
PMID: 39991154
[This corrects the article DOI: 10.3389/fimmu.2024.1439413.].
2.
Reste M, Ajazi K, Sayi-Yazgan A, Jankovic R, Bufan B, Brandau S, et al.
Front Immunol
. 2024 Nov;
15:1439413.
PMID: 39483484
Tertiary Lymphoid Structures (TLS) are organized aggregates of immune cells such as T cells, B cells, and Dendritic Cells (DCs), as well as fibroblasts, formed postnatally in response to signals...
3.
Ascic E, Akerstrom F, Sreekumar Nair M, Rosa A, Kurochkin I, Zimmermannova O, et al.
Science
. 2024 Sep;
386(6719):eadn9083.
PMID: 39236156
Immunotherapy can lead to long-term survival for some cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here,...
4.
Andersson H, Nyesiga B, Hermodsson T, Enell Smith K, Hagerbrand K, Lindstedt M, et al.
Expert Opin Biol Ther
. 2024 May;
24(5):351-363.
PMID: 38764393
Introduction: There is a need for new therapies that can enhance response rates and broaden the number of cancer indications where immunotherapies provide clinical benefit. CD40 targeting therapies provide an...
5.
Roser L, Sakellariou C, Lindstedt M, Neuhaus V, Dehmel S, Sommer C, et al.
J Immunotoxicol
. 2024 Apr;
21(1):2332177.
PMID: 38578203
Drug-induced hepatotoxicity constitutes a major reason for non-approval and post-marketing withdrawal of pharmaceuticals. In many cases, preclinical models lack predictive capacity for hepatic damage in humans. A vital concern is...
6.
Sakellariou C, Roser L, Schiffmann S, Lindstedt M
J Immunotoxicol
. 2024 Mar;
21(1):2332175.
PMID: 38526995
Novel immunotherapies for cancer and other diseases aim to trigger the immune system to produce durable responses, while overcoming the immunosuppression that may contribute to disease severity, and in parallel...
7.
Li N, Chamkha I, Verma G, Swoboda S, Lindstedt M, Greiff L, et al.
Front Oncol
. 2024 Jan;
13:1304106.
PMID: 38273844
Introduction: Head and neck squamous cell carcinoma (HNSCC) constitutes a heterogeneous group of cancers. Human papilloma virus (HPV) is associated with a subtype of HNSCC with a better response to...
8.
Altunbulakli C, Jimenez D, Askmyr D, Sobti A, Swoboda S, Greiff L, et al.
Front Oncol
. 2023 Dec;
13:1253418.
PMID: 38044986
Background: Tonsillar cancer is caused by high-risk human papillomavirus (HPV), tobacco smoking, and alcohol abuse. Aspects of the patient's immune response to this disease have arisen as prognostic factors and...
9.
Andersson H, Sobti A, Jimenez D, Pico de Coana Y, Ambarkhane S, Hagerbrand K, et al.
Cells
. 2023 Oct;
12(19).
PMID: 37830579
CD40-targeting therapies can enhance the dendritic cell priming of tumor-specific T cells and repolarize intratumoral macrophages to alleviate the tumoral immunosuppressive environment and remodel the extracellular matrix. Mitazalimab is a...
10.
Zimmermannova O, Ferreira A, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, et al.
Sci Immunol
. 2023 Jul;
8(85):eadd4817.
PMID: 37418548
Decreased antigen presentation contributes to the ability of cancer cells to evade the immune system. We used the minimal gene regulatory network of type 1 conventional dendritic cells (cDC1) to...